Compass Therapeutics Shares Rise 7.4%, Analysts Still Bullish

The biotech company's stock price jumped after a positive earnings report, but analysts maintain their buy recommendations.

Apr. 18, 2026 at 11:22am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex, industrial-looking piece of medical equipment or laboratory apparatus, rendered in high detail and dramatic lighting to symbolize the advanced science and technology behind Compass Therapeutics' drug development.Compass Therapeutics' cutting-edge biotech research and development is reflected in the intricate machinery powering its innovative drug pipeline.Cambridge Today

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) rose 7.4% during mid-day trading on Thursday, reaching as high as $6.18 per share before closing at $6.2850. The jump came after the company reported better-than-expected earnings, with the stock trading on higher than average volume. Despite the gains, analysts remain bullish on Compass Therapeutics, with a consensus 'Moderate Buy' rating and an average price target of $14.20.

Why it matters

Compass Therapeutics is a clinical-stage biotech company focused on developing novel immuno-oncology therapies. The positive stock performance and continued analyst optimism suggest the company's pipeline and technology are resonating with the market, even as it navigates the competitive biotech landscape.

The details

Compass Therapeutics reported Q1 earnings on March 5th, posting a loss of $0.09 per share, which beat analyst estimates of a $0.10 per share loss. The company's lead programs include CTX-471, a bispecific antibody targeting PD-1 and PD-L1 checkpoints, and DSP107, a CD47-SIRP? pathway modulator. Analysts have cited the company's proprietary antibody platforms and focus on innovative immuno-oncology approaches as reasons for their bullish outlooks.

  • Compass Therapeutics shares rose 7.4% during mid-day trading on Thursday, April 18, 2026.
  • The company reported Q1 2026 earnings on March 5, 2026.

The players

Compass Therapeutics, Inc.

A clinical-stage biotechnology company dedicated to developing novel immuno-oncology therapies, headquartered in Cambridge, Massachusetts.

D. Boral Capital

A financial research firm that has issued a 'buy' rating and $30 price target on Compass Therapeutics shares.

Jefferies Financial Group

An investment bank that has reiterated a 'buy' rating and $9 price target on Compass Therapeutics.

Craig Hallum

An investment research firm that initiated coverage on Compass Therapeutics with a 'buy' rating and $15 price target.

Weiss Ratings

A financial research firm that has issued a 'sell (d-)' rating on Compass Therapeutics shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Compass Therapeutics' positive stock performance and continued analyst optimism suggest the company's innovative immuno-oncology pipeline and proprietary technology platforms are resonating with the market, even as it navigates the competitive biotech landscape.